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Abstract
Somatic activating mutations within the PIK3CA gene have been recently detected in sporadic lymphatic and venous
malformations, and in vascular malformations (VM) associated to overgrowth syndromes, such as CLOVES and
Klippel–Trenaunay syndrome. Although VM are often limited to specific tissue areas and can be well treated, in
extended or recurrent lesions novel therapeutic approaches are needed. We generated a mouse model of VM by local
expression of PIK3CA-activating mutation in endothelial cells. PIK3CA-driven lesions are characterized by large areas of
hemorrhage, hyperplastic vessels, infiltrates of inflammatory cells, and elevated endothelial cell density. Such vascular
lesions are ameliorated by administration of dual PI3K/mTOR inhibitor, BEZ235, and mTOR inhibitor, Everolimus.
Unexpectedly, the expression of PIK3CA-activating mutations in human endothelial cells results in both increased
proliferation rates and senescence. Moreover, active forms of PIK3CA strongly promote the angiogenic sprouting.
Treatment with PI3K/mTOR inhibitors restores normal endothelial cell proliferation rate and reduces the amount of
senescent cells, whereas treatment with Akt inhibitor is less effective. Our findings reveal that PIK3CA mutations have a
key role in the pathogenesis of VM and PIK3CA-driven experimental lesions can be effectively treated by PI3K/mTOR
inhibitors.
Introduction
Somatic mutations within the phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)
gene, coding for the p110α catalytic subunit of class 1A
phosphoinositide-3-kinase (PI3K), are frequently found in
human tumors1. Most of these are activating mutations,
clustering in two hot spot regions in helical (E542 and
E545) and kinase domains (H1047) of the PI3K protein2.
Recently, numerous studies reported the presence of
somatic PIK3CA-activating mutations, including those
traditionally defined as “cancer-associated”, in several
genetic syndromes characterized by overgrowth3. The
identification of PIK3CA somatic mutations in syndromes
with distinct, but partially overlapping, clinical findings,
such as Fibroadipose hyperplasia or Overgrowth4,
CLOVES syndrome5, macrodactyly and muscle hemi-
hypertrophy6, Megalencephaly-Capillary Malformation7,
and hemimegalencephaly8, suggested to group all of these
syndromes and term them “PIK3CA-related overgrowth
spectrum” (PROS)3.
Most PROS syndromes are characterized by vascular
malformations (VMs), suggesting that PIK3CA somatic
mutations could occur in vascular endothelial cells (EC).
Indeed, PIK3CA-activating mutations have been detected
in lymphatic EC isolated from tissues of PROS syn-
dromes9, and in lymphatic and venous malformations
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which arise as an isolated VM10–13. Furthermore, earlier
studies on mouse models showed that alteration of PI3K
signaling resulted in severe vascular defects. For example,
mice deficient in the p110α catalytic subunit of PI3K,
display multiple vascular defects, including dilated vessels
in the head and reduced branching morphogenesis in
the endocardium14. Interestingly, only p110α activity,
but not p110β and p110γ, is essential for vascular devel-
opment15. Similarly, mice deficient in expression of
PI3K regulatory subunits in ECs display a vascular
phenotype during development as well as during tumor
neovascularization16.
Accumulating studies suggest a critical role for muta-
tions in PIK3CA gene as driver event in vascular diseases.
Cellular and mouse models expressing PIK3CA-activating
mutations are characterized by serious phenotypic
alterations, strongly supporting the causative effect of
these mutations in the pathogenesis of PROS syndromes
and VMs11–13,17,18.
However, biological mechanisms involved in the
pathogenesis of VMs, both sporadic and associated to
other defects, are poorly described.
To overcome these limitations we combined the design
of genetically modified mouse models with conditional
endothelium-specific expression of PIK3CA-activating
mutations and the use of primary endothelial cultures.
Our mouse models allow to mimic a localized disease by
ectopic activation of the mutation and to verify the role of
such mutations in vascular development. We show that
expression of PIK3CA-activating mutations in human ECs
results in both increased proliferation rates and senes-
cence. We report evidence of treatment efficacy of PI3K/
mTOR inhibitors both in vitro and in vivo by reverting
morphology and functionality of altered ECs and
vasculature.
Results
Endothelial expression of Pik3caH1047R mutation is
embryonically lethal
We investigated the effects of PIK3CA-activating
mutations on vascular development in vivo by crossing
Pik3caH1047R mice to the Tie2Cre mouse strain, in which
Cre expression is restricted to endothelial compartment.
This promoter is not completely specific for ECs but has
the advantage of being expressed during early develop-
ment19. Cre-mediated deletion of loxP-flanked transcrip-
tional stop cassette allows for tissue-specific expression of
the mutant allele.
No Tie2Cre:Pik3caH1047R pups were born and long-
itudinal analysis of embryos revealed that lethality was
occurring prior to E10.5 (Fig. 1a). At E9.5, mutant
embryos were smaller and developmentally delayed
compared to wild-type litter-mates (Fig. 1b). Although
E9.5 Tie2Cre:Pik3caH1047R mutant embryos were observed
to have a heartbeat, they showed a disorganized and
truncated vascular network (Fig. 1b). Whole-mount
staining for ECs revealed that mutant embryos had
Fig. 1 Mice expressing Pik3caH1047R in developing and adult
vascular EC are not viable. a Transgenic mice that express latent
Pik3caH1047R mutant allele (H1047R) were crossed with mice expressing
Cre recombinase under endothelial promoter (Tie2Cre). The Mendelian
expected ratio for endothelial Pik3caH1047R allele was the 50% of
newborn mice, but only mice carrying wild-type alleles were
identified. b We recovered live embryos with PIK3CA mutations until
mouse embryonic day 9.5. These embryos showed growth delay (top)
and evident vascular defects (bottom, in red endomucin staining).
c Transgenic mice that express latent Pik3caH1047R mutant allele
(H1047R) were crossed with mice expressing Tamoxifen-inducible
Cre recombinase under VE-Cadherin promoter (Cdh5-CreERT2). Mice
treated with single administration of Tamoxifen did not survive
>2 weeks after Cre induction
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formed the major vessel branches of the dorsal aorta and
anterior cardinal veins but had failed to undergo vessel
remodeling and sprouting in the head, somites and dorsal
regions of the embryo (Fig. 1b).
The lethal phenotype is consistent with the fact that
genetic evidence of heritable syndromes with activating
mutation in PIK3CA gene has never been reported. In
contrast, postzygotic mutations have recently been descri-
bed in PROS syndromes5. With this motivation in mind we
evaluated the effects of Pik3caH1047R mutation in the adult
vasculature. By crossing Pik3caH1047R mice to mice
expressing a Tamoxifen-inducible recombinase Cre under
control of VE-cadherin promoter (Cdh5-CreERT2) we
were able to obtain conditional expression of PIK3CA-
activating mutation in vascular ECs upon administration of
Tamoxifen. We treated mice with a single intraperitoneal
administration of Tamoxifen resulting in 100% of mortality
in Pik3caH1047R/ Cdh5-CreERT2 mice at 15 days after
injection (Fig. 1c). In contrast Pik3cawt/ Cdh5-CreERT2
mice did not show any sign of suffering and appeared
completely normal. To understand the cause of death of
Pik3caH1047R/ Cdh5-CreERT2 mice, we sacrificed three
mice 13 days after Tamoxifen administration and we
analyzed multiple organs. We observed signs of a cardiac
degenerative process, with small spots of fibrosis (Fig. S1A,
circled areas) and vacuolated cardiomyocytes (Fig. S1A’,
arrows). Conversely, the other organs analyzed (brain, liver,
kidneys, spleen, lungs) did not show any defects.
PIK3CA-activating mutations induce both cell senescence
and proliferation in ECs
To investigate in detail the effects of PIK3CA-activating
mutations in the endothelium, we expressed H1047R
mutant in human umbilical vein endothelial cells
(HUVEC) by retroviral infection. We also generated cells
expressing PIK3CA-E545K, a different activating mutation
detected in VM syndromes. As control cells, we used
HUVECs infected with an empty retroviral vector alone or
one expressing wild-type human PIK3CA (Fig. S1B). The
expression of active PI3K evidently modified EC mor-
phology by dramatically increasing average cell size.
Among those expressing PIK3CA-H1047R and PIK3CA-
E545K, we observed several large cells, while the expres-
sion of wild-type PIK3CA did not induce any obvious
morphological abnormality (Fig. 2a). We measured the
adhered cell surface and we observed a twofold increase of
total area in EC-H1047R and EC-E545K compared with
PIK3CA-WT or empty vector expressing EC (Fig. 2b)
plated at the same cell density. Interestingly, the larger
surface occupied by EC-expressing PIK3CA mutants is
mainly caused by the increased size of a small amount of
cells, as shown by flow-cytometric analysis (Fig. 2c). These
cells showed several phenotypic aspects normally asso-
ciated to senescence, such as the presence of a large
number of internal vesicles, the increased cell size and,
frequently, the presence of multiple nuclei. Therefore we
evaluated the expression of β-galactosidase, a recognized
senescence marker, on PIK3CA-mutant EC20. Indeed the
expression of active PI3K, both H1047R and E545K
mutants, increased the amount of β-galactosidase positive
cells (Fig. 2d and S1C–D).
Cell senescence is commonly characterized by low
replicative rates, so we expected to find reduced pro-
liferation rates in EC-expressing active PI3K. Instead, in
presence of vascular endothelial growth factor (VEGF)-A,
overall, cells were found to proliferate more rapidly than
normal EC or EC-expressing PIK3CA-WT (Fig. 3a and
S1E). To decouple the potential effect of increased cell
surface from that of increased proliferation rates in these
conditions, we measured DNA replication rates by means
of EdU incorporation assay. EC-H1047R and EC-E545K
showed higher DNA replication rates, which were parti-
cularly elevated when EC were stimulated with VEGF-A
(Fig. 3b). The increase of DNA replication even in absence
of VEGF-A is apparently in contrast with results pre-
sented in Fig. 2b that shows lack of area change in the
different cell lines overtime. However, the time variation
of the total area covered by cells is due to both pro-
liferation and the balance between normal and senescent
cells in the population. Interestingly the coexistence of
highly proliferating and senescent cells is consistent with
non-neoplastic lesions observed in human syndromes. To
support this idea, we analyzed the cell size of EdU-positive
EC stimulated with VEGF-A (Fig. 3c). To elucidate
(see figure on previous page)
Fig. 2 PIK3CA-activating mutations induce morphological alterations and senescence in EC. a Human primary endothelial cells were
transduced with retroviral vectors carrying activating mutations of PIK3CA (PIK3CA-H1047R and PIK3CA-E545K), wild-type PIK3CA (WT), or with empty
vector. EC-expressing PIK3CA mutants showed morphological alterations. Large cells with abnormal stress fibers and intracellular vesicles are
observable (green: Phalloidin, red: vinculin, blue: DAPI). Scale bar 50 µm. b Cell surface area is measured in real-time by impedance system with
xCELLigence technology in absence of growth factors. EC-H1047R and EC-E545K adhere on substrate and occupy more surface than EC-WT or
normal cells. Data were plotted as the mean cell index from three wells at each time points; P-values were calculated at 24 h, *P < 0.005, vs. control
wild-type PIK3CA endothelial cells. c Transduced EC are analyzed by flow cytometer for forward scatter intensity. The expression of PIK3CA mutants
increase the percentage of cells with higher volume as indicated. The reported experiments are representative of three independent experiments.
d β-galactosidase staining show senescent cells. Image manipulation has been done to highlight positive cells, as described in the Methods section.
Original pictures are in supplemental Fig. 1c
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whether large putatively senescent cells are also non-
proliferating, we calculated the percentage of large cells
(area >5000µm2) that were positive for EdU, and we
obtained that only (11.1±4.8)% of EC-H1047R and (12.5
±3.0)% of EC-E545K were proliferating among the large
cells while the corresponding percentages among normal
cells were (21.4±2.2)% and (26.7±2.1)%, respectively.
Therefore, the likelihood of being proliferating among
large cells is roughly twice as small as for normal cells,
thus reinforcing the notion that putative senescent cells
are for the majority non-proliferating (Fig. 3c).
ECs expressing PIK3CA-activating mutations sprout
forming capillary-like structures
To assess the possible relevance of morphological and
proliferative alterations induced by PIK3CA mutations in
physiological endothelial processes, we used an angio-
genesis sprouting assay. In this assay EC spheroids,
embedded in a collagen gel, generate multicellular pro-
trusions, reminiscent of sprouting capillaries. Normal
EC spheroids, as well as those expressing PIK3CA-WT,
formed sprouts only when stimulated by VEGF-A
(Fig. 3d–f). Surprisingly, spheroids of EC-expressing
active forms of PI3K produced many sprouts even in
absence of angiogenic stimuli, while the addition of
VEGF-A induced a larger number of capillary-like struc-
tures than in control EC (Fig. 3d–f). Excessive sprouting
angiogenesis could be either caused by greater ability of
EC to migrate or by increased proliferation alone. To
investigate the role of EC migration, we performed a
chemotaxis assay where EC are induced to migrate
directionally by a spatial gradient of VEGF-A (Fig. 3g).
Both wild-type PI3K and active mutants increased moti-
lity of EC in presence of VEGF-A but, according to our
experiments, EC-H1047R and EC- E545K did not show
significant difference in migratory ability compared to
cells expressing PIK3CA-WT (Fig. 3g). This result sug-
gested a prominent role for cell proliferation in increased
angiogenic sprouting caused by PIK3CA-activating
mutants.
Localized expression of Pik3caH1047R in mice induces VMs
The lethal phenotype obtained with the expression of
Pik3caH1047R in whole vascular endothelium both during
development and in adult mice, prompted us to conceive
a model in which the expression was spatially confined.
For this reason, we intramuscularly injected posterior legs
of Pik3caH1047R/ Cdh5-CreERT2 mice with 4-OH
Tamoxifen. A single administration was sufficient to
induce the appearance of evident signs of bleeding and
vessel abnormalities after 1 week (Fig. 4a). Hystopatho-
logical analysis revealed enlarged vessels and increased
vessel density with angiomatous lesions, and large areas of
infiltrated inflammatory cells (Fig. 4b). In pathological
tissues, vessels are formed by a thick heterogeneous layer
of EC, frequently disorganized and discontinuous, with
the presence of clusters of cells heterogeneous in size
(Fig. 4c–e). Large vessels appeared dilated, occasionally
forming hemangioma-like structures (Fig. 4c–e). More-
over, pathological lesions showed recruitment of inflam-
matory cells potentially caused by production of
chemoattractant molecules (Fig. 4f, g). Notably, the
secretion of cytokines is one of the recognized signs of
senescence, so-called secretory associated senescence
phenotype21. In fact, tissues from 4-OH Tamoxifen-trea-
ted mice showed positivity for β-galactosidase staining
(Fig. S1F) and increased β-galactosidase activity
(Fig. S1G). Moreover, the senescence marker p15INK4B
clearly accumulated in pathological tissue (Fig. S1H).
The dual PI3K/mTOR inhibitor BEZ235 completely rescues
the cell phenotype induced by PIK3CA-activating
mutations
Taking advantage of the availability of several inhibitors
of PI3K/mTOR signaling pathway developed as cancer
drugs, we specifically evaluated the effect of Everolimus
(see figure on previous page)
Fig. 3 PIK3CA-activating mutations increase proliferation rate and sprouting formation. a Cell surface area is measured in real-time by
impedance system with xCELLigence technology in presence of VEGF-A. EC- H1047R and EC-E545K grew faster than EC-WT or normal cells. Slopes for
each sample are reported in supplemental Fig. 1e. b DNA replication rate was quantified by Click-iT EdU Alexa Fluor 647 Imaging kit. EC-H1047R and
EC-E545K showed higher DNA replication rates. The percentage of EdU-positive nuclei is indicated in the graph. Data were plotted as the mean from
three independent experiments; *P < 0.005 and §P < 0.001, vs. control wild-type PIK3CA endothelial cells. c After Click-iT EdU assay, VEGF-A-stimulated
EdU-positive cells are divided into two categories: normal ( < 5000 µm2) and large (>5000 µm2); the percentage of positive large cells among the total
number of large cells, and correspondingly the percentage of positive normal cells among the total number of normal cells was calculated. For each
category, total number of cells in the category is indicated on the top of the graph area. d Spheroids of the indicated EC were embedded in a
collagen gel and stimulated or not with VEGF-A to generate capillary-like sprouts. Spheroids of EC-expressing active forms of PIK3CA produced
sprouts even in absence of VEGF-A. e Quantification of spheroids growth. Equivalent radii of the spheroids were normalized with control average
radius (unstimulated empty vector EC). f To quantify the sprouting, an aspect ratio measure was used, defined as the ratio between the equivalent
ratios obtained by perimeter and area of the spheroids. g Chemotaxis assay was performed by means of Boyden Chamber; EC were induced to
migrate by VEGF-A. Data were plotted as the mean from three independent experiments; §P < 0.001, vs. endothelial cells transduced with empty
vector
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(mTOR inhibitor) MK2206 (Akt inhibitor) and BEZ235
(double mTOR/PI3K inhibitor) on our models. Treat-
ments with MK2206 and BEZ235 were able to blunt Akt
phosphorylation in parental and PI3K WT-expressing EC,
whereas in EC-H1047R and EC-E545K Akt phosphor-
ylation level was only partially reduced (Fig. 5a and S2A).
EC treated with Everolimus or BEZ235 showed also a
decreased phosphorylation of S6, a substrate of mTOR
(Fig. 5a and S2B). However, in EC-H1047R and EC-
E545K, phospho-S6 was not reduced by treatment with
these inhibitors. Conversely, BEZ235 was able to reduce
the phosphorylation of another substrate of mTOR,
4EBP1, both on serine 65 and threonines 37 and 46, also
in EC-H1047R and EC-E545K (Fig. 5a and S2B). Similar
signal alterations were also observed in absence of VEGF-
A stimulation (Fig. S2C-E).
Despite the limited efficacy of these drugs in inhibiting
the signaling pathway activated by mutated PIK3CA, the
biological effects on EC were impressive. Treatment with
BEZ235 rescued the phenotype induced by PIK3CA-
H1047R or PIK3CA-E545K expression, completely inhi-
biting cell proliferation in VEGF-A-stimulated conditions
(Fig. 5b). Similar results were obtained with Everolimus,
which completely abrogates the proliferation increase
induced by PIK3CA-activating mutations. In contrast, Akt
inhibition only partially reduced the proliferation of EC-
expressing both PIK3CA-WT and PIK3CA mutants and
was less effective, compared with the other two inhibitors,
to reduce the proliferation rate of VEGF-A stimulated
normal EC (Fig. 5b). Interestingly, BEZ235-treated cells
recovered normal cellular size just after 72 h of treatment
with a clear reduction of the number of large/senescent
cells (Fig. 5c and S3A–C). Time-lapse microscopy
experiments showed that in presence of BEZ235, senes-
cent cells rapidly died while non-senescent cells stopped
to proliferate (Supplementary movies 1–4). Treatment
with BEZ235 and Everolimus was also able to reduce the
angiogenic sprouting from spheroids of EC stimulated
with VEGF-A (Fig. S3D-E).
Vascular PIK3CA-driven lesions are ameliorated by BEZ235
administration
The impressive results obtained by treating EC-
expressing PIK3CA mutations with BEZ235 or Ever-
olimus prompted us to evaluate its effect on in vivo
vascular lesions. Localized Pik3caH1047R expression was
induced in mice by 4-OH Tamoxifen injection in the
posterior leg. One week later we started the treatment
with BEZ235 or Everolimus. Examination of explanted leg
muscles indicated that both treatments reduced vascu-
larization and bleeding (Fig. 6a). Analysis of histological
sections confirmed this evaluation showing normalization
of tissue treated with BEZ235, although large infiltrates of
immune cells were still present (Fig. 6b). The effects of
Everolimus were less pronounced, with histological sec-
tions still characterized by extensive areas of pathologic
tissue and bleeding (Fig. 6b). Notably, both treatments did
not simply block the progression of vascular lesions but
reduced the entity of the pathological traits, and re-
established a normally vascularized tissue (Fig. 6c), as it
was also demonstrated by the quantification of CD31-
positive microvessel density (Fig. 6d, e).
Discussion
Vascular anomalies, including both vascular tumors and
malformations represent a broad spectrum of disorders
ranging from a simple “birthmark” to life-threatening
entities22. These diseases frequently affect infants and
children but symptoms can also become apparent in
young adults. VMs are often limited to specific tissue
areas and can be treated in severe cases by surgical
resection or sclerotherapy. However, in extended or
recurrent lesions, alternative therapeutic approaches are
needed. Unfortunately, no drugs have been proven to be
effective so far.
Germline and somatic activating mutations in the gene
encoding the EC tyrosine kinase receptor Tie2 have been
reported to be causative for familial and for some sporadic
venous malformations, respectively23,24. More recently,
the discovery of somatic activating mutations of PIK3CA
gene in venous and lymphatic malformations has opened
new perspectives for therapeutic options9–13.
Here we showed that expression of PIK3CA-activating
mutations in human EC induced hyperproliferation and
concomitant cellular senescence. PIK3CA-induced
senescent cells are larger than normal EC and are char-
acterized by many intracellular vesicles and elevated β-
galactosidase activity. Oncogene-induced senescence was
described >10 years ago for the Ras oncogene in human
fibroblasts25, whereas there is no clear evidence for a role
(see figure on previous page)
Fig. 4 Localized expression of Pik3caH1047R in mice induces vascular malformations. a, b Vehicle or 4-OH Tamoxifen were locally injected in
posterior limbs of Pik3caH1047R/Cdh5-CreERT2 mice. After 1 week, animals were sacrificed and muscles were dissected and analyzed by H&E staining. c
Vessels of the same samples were analyzed by immunohistochemistry with anti-CD146 antibody. d, f Frozen tissues of vehicle or 4-OH Tamoxifen-
injected mice were analyzed by immunofluorescence with anti-IB4 to stain vessels (green in d, scale bar 100 µm) and anti-CD45 to stain recruited
inflammatory cells (magenta in f, scale bar 100 µm). e, g Quantification of microvessel area (IB4-positive area in the total field area) and CD45-positive
area in samples from vehicle or 4-OH Tamoxifen-injected mice; §P < 0.005, vs. vehicle treated
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of PI3K signaling in cell senescence26. However, recent
interesting studies showed that treatment of senescent
cells with the mTOR inhibitor abrogates the senescent-
associated secretory phenotype, whereas cell cycle arrest
remains unaffected27,28. Our observations indicate that a
constitutive active PI3K signaling is able to promote the
Fig. 5 The dual PI3K/mTOR inhibitor BEZ235 rescues the cell phenotype induced by PIK3CA-activating mutations. a EC were serum starved
and then stimulated with VEGF-A in presence or absence of the indicated inhibitors (BEZ235, Everolimus, MK2206); corresponding lysates were then
separated by SDS-PAGE and analyzed with the indicated antibodies. b DNA replication rate was measured by Click-iT EdU Alexa Fluor 647 Imaging kit
after treatment of EC with the indicated inhibitors. The percentage of EdU-positive nuclei is indicated in the graph. Data were plotted as the mean
from three independent experiments; *P < 0.001 and §P < 0.05, vs. the same VEGF-stimulated and untreated cells. c EC treated with the indicated
inhibitors were analyzed by flow cytometer. The percentage of cells with linear Forward Scatter > 150 (large cells) is indicated in the graph. Data were
plotted as the mean from three independent experiments; *P < 0.01 and §P < 0.05, vs. the same VEGF-stimulated and untreated cells
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emergence of non-proliferating, senescent cells in absence
of global reduction of endothelial proliferation. We can
speculate that concomitant EC senescence and prolifera-
tion might limit VMs to hyperplastic forms, such as
enlarged vessels or clusters of EC, without progressing
towards more aggressive neoplastic forms. Notably,
treatment with Everolimus, which block mTOR1, com-
pletely restores the normal proliferation rate in EC-
expressing PIK3CA mutations but appears less effective in
hampering cell senescence. Instead, the PI3K/mTOR
inhibitor BEZ235 eliminates all senescent cells, rapidly
inducing their apoptosis.
How can this phenotype of mixed proliferating/senes-
cent cell affect the functionality of EC? The most striking
result is the increased in vitro 3D sprouting induced by
VEGF-A. Even more impressive is that mutant EC were
able to form new sprouts even in the absence of VEGF-A.
The role of PIK3CA in angiogenesis both during devel-
opment and tumor progression is well established29.
However, traditionally, VMs are lesions composed only of
mature vessels, although microvascular proliferation in up
to 30% of congenital VMs has been reported, especially in
those with a significant arteriovenous component30. High
density of small EC clusters, which are bona fide new
capillaries, is evident also in our animal model. Our model
is generated by local expression in mouse limb of Pik3-
caH1047R in VE-cadherin-positive EC, and is characterized
by large areas of hemorrhage, hyperplastic vessels, infil-
trates of inflammatory cells and, precisely, elevated EC
density. These pathological properties mirror several
clinical signs observed in patients with VMs, although the
diversity of diseases classified as VMs makes it difficult to
associate our model to a specific syndrome31. Moreover,
VE-cadherin is commonly expressed in all vessels,
including veins, arteries, capillaries and lymphatics, thus
our model do not precisely phenocopy venous, lymphatic
or capillary malformations but represents a mixed vas-
cular disease.
It is interesting that PIK3CA-activating mutations have
been detected in PROS syndromes, which are frequently
characterized by VM such as CLOVES and
Klippel–Trenaunay syndromes9, but in which other cel-
lular types are affected as well. What is the relation
between PIK3CA-activating mutations in EC and the
pathogenesis of PROS is not known.
One hypothesis is that mutations arise in progenitors
cells able to differentiate to several cell types, including
EC, and that the severity of the disease could depend on
the period of emergence of mutation. Indeed, our mice
model of constitutive expression in EC of PIK3CAH1047R
in Tie2-positive and VE-cadherin-positive cells together
indicates that broad and early expression of PIK3-
CAH1047R during development is not compatible with life.
These results are in agreement with recent published
results and are consistent with the lack of reported her-
editary diseases driven by mutations in the PIK3CA
gene17.
Particularly interesting are the results obtained by
treating mice with BEZ235 or Everolimus. Indeed,
BEZ235 is particularly effective to reduce the lesions
induced by active PIK3CA, and allows an almost complete
recovering of the normal phenotype with only residual
infiltrate of inflammatory cells. Similarly, mice treated
with Everolimus showed signs of disease regression
although hemorrhage and vascular alterations were still
present. These observations are extremely relevant from a
translational point of view. Although clinical trials with
Everolimus-analogs in patients with VMs and PROS
syndromes are ongoing, to our best knowledge no clinical
study is currently evaluating PI3K-inhibitors or PI3K/
mTOR inhibitors, such as BEZ235. Further preclinical
experiments with these drugs on models of PIK3CA-
driven diseases would prompt new clinical trials, which
could change the management of these syndromes.
Materials and methods
Mice strains and treatment
R26-Pik3caH1047R strain was purchased from Jackson
Laboratory. These mice carry loxP-flanked transcriptional
stop cassette upstream of the H1047R mutant allele of
Pik3ca within the Gt(ROSA)26Sor locus32. The Tie2Cre
transgenic mice (Jackson Laboratory) have the mouse
endothelial-specific tyrosine kinase receptor Tie2 promoter
directing the expression of Cre recombinase19. R26-Pik3-
caH1047R and Tie2Cre transgenic mice were crossed to
obtain the endothelial expression of H1047R mutant allele
during embryogenesis. The progeny was analyzed post-
natally and at different developmental stages (E9.5, 10.5, and
13.5) by genotyping and whole-mount immunofluorescence
of the embryos. Cdh5-CreERT2 mice (kindly provided by
(see figure on previous page)
Fig. 6 Vascular PIK3CA-driven lesions are ameliorated by BEZ235 administration. a, b Localized Pik3caH1047R expression was induced in mice by
4-OH Tamoxifen injection in the posterior leg. One week later, we started the treatment with BEZ235 or Everolimus. Explanted muscles were
examined and sections of the same tissues were analyzed by H&E. c Vessels of the same samples were analyzed by immunohistochemistry with anti-
CD146 antibody. d Frozen tissues of vehicle or 4-OH Tamoxifen-injected mice, treated or not with BEZ235 or Everolimus, were analyzed by
immunofluorescence with anti-CD31 to stain vessels (in green, merged with DAPI in blue). e Microvessel area (CD31-positive area in the total field
area) was quantified; §P < 0.05, vs. vehicle treated, *P < 0.05 vs. Tamoxifen treated
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professor R. Adams) have the Tamoxifen-inducible Cre
recombinase (CreERT2) under the regulation of the vascular
endothelial cadherin promoter (Cdh5)33. R26-Pik3caH1047R
and Cdh5-CreERT2 mice were crossed to induce the
endothelial expression of H1047R mutant allele during
adulthood. After genotyping, 8–10 weeks of age mice car-
rying both the transgenes and control mice were intraper-
itoneal injected with 1mg Tamoxifen (Sigma, dissolved in
ethanol/peanut oil [10:90 v/v]) for either 5 consecutive days
or only 1 day to induce systemic endothelial expression of
mutant PIK3CA protein. After 13 days, mice were killed and
different tissues (heart, brain, liver, kidneys, spleen, lungs)
were dissected and analyzed by H&E staining. Alternatively,
posterior left limbs of 8–10 weeks of age mice carrying both
the transgenes and control mice were injected once with 1
mg 4-OH Tamoxifen (Sigma, 10 μg/μl in ethanol) to induce
local endothelial expression of mutant PIK3CA protein into
the muscle. After 15 days, the latter mice were sacrificed and
the tissue was analyzed by immunohistochemistry. When
used, BEZ235 and Everolimus were administered to mice by
oral gavage as follow: BEZ235 at the dose of 25 mg/kg in
NMP (N-Methyl-2-pyrrolidone)/PEG300 (Poly Ethylene
Glycol 300) (10/90 v/v), Everolimus at the dose of 5mg/kg
in phosphate-buffered saline (PBS), both for 7 consecutive
days, 1 week after 4-OH Tamoxifen injection. All the gen-
otype analysis was performed by PCR amplification follow-
ing providers’ instructions. All animals were maintained in
the animal facility of the Candiolo Cancer Institute under
germ-free housing conditions. All animal experiments were
performed in compliance with guidelines governing the care
of laboratory mice and approved by Italian Ministry of
Health.
Whole-mount embryo immunofluorescence
Freshly isolated embryos were fixed overnight in 4%
paraformaldehyde at 4° C, washed in PBT (PBS, 0.1%
Tween 20) and subjected to dehydration in increasing
methanol concentration (50%, 80% methanol/PBT, 100%
methanol) followed by rehydration in decreasing metha-
nol concentration (80%, 50% methanol/PBT, PBT). After
washing in Pblec (PBS pH 6.8, 1% Tween 20, 1 mM CaCl2,
1 mM MgCl2, 0.1 mM MnCl2), the embryos were incu-
bated overnight at 4° C in the presence of rat anti-mouse
endomucin (Santa Cruz Biotecnologies) diluted 1:20 in
Pblec. After five washes in PBT, embryos were incubated
overnight at 4° C with goat anti-rat Alexa 555 (Thermo-
Fisher Scientific) diluted 1:100 in PBS, 0.5% BSA and
0.25% Tween 20, followed by washing in PBT and post-
fixation in 4% paraformaldehyde before analysis.
Immunohistochemistry analysis
Paraffin samples of mice limbs from each group of treat-
ment were serially cut (10 μm) and rehydrated through 100%
xylene and 100, 95, and 70% ethanol before immersion in
H2O. Sections were then stained with hematoxylin and eosin
(H&E) and dehydrated. Rabbit anti-CD146 antibody
(Abcam) to bind vessels and rabbit anti- p15INK4B antibody
(ThermoFisher Scientific) to visualize senescent cells were
used, after heat-induced epitope retrieval in sodium citrate
buffer (1mM sodium citrate, pH 6.6), inactivation of
endogenous peroxidases in 3% H2O2 and blocking in TBS/
0.1% Tween/0.3% Triton/5% goat serum. HRP-conjugated
goat anti-rabbit secondary antibody and DAB (3,3′-Diami-
nobenzidine) substrate were used to stain vessels.
Cell culture
Human EC were isolated from umbilical cord veins,
characterized and grown in M199 (Sigma) containing 20%
fetal bovine serum (FBS, ThermoFisher Scientific), bovine
brain extract, heparin (50 μg/ml, Sigma) and
penicillin–streptomycin (200 U/ml, Sigma) on 1% gelatin-
coated tissue culture dishes, as previously described34.
Gryphon amphotropic packaging cells were grown in
IMDM (Sigma) supplemented with 10% FBS, L-Glutamine
(2 mM, Sigma) and antibiotics. β-galactosidase staining
was performed with the Cell Signaling Technology
Senescence staining kit following manufacturer instruc-
tions. To enhance contrast of β-galactosidase staining we
removed background and enhanced contrast in each
channel (R, G, B). The same values of relative contrast
were used on all images. Original pictures are reported in
fig S1C and S3B. Quantification of the staining was done
by manually counting positive and negative cells in at least
six images for each condition from two independent
experiments. Furthermore, β-galactosidase activity was
also evaluated on either cell- or tissue-lysates using
Mammalian β-galactosidase Assay Kit (ThermoFisher
Scientific) following manufacturer instructions, with the
exception of incubation time that was extended to 24 h.
Retroviral vector construct and EC infection
The cDNAs of wild-type and mutant PIK3CA (E545K
and H1047R) inserted into the pBabe retroviral vector
were purchased from Addgene. The amphotropic cell line
Gryphon was transfected with retroviral vectors, and the
retroviral supernatants obtained were collected, filtered
and supplemented with 4 μg/ml of polybrene (Sigma-
Aldrich). Medium of EC were replaced with the appro-
priate retroviral supernatants, and cells were incubated at
37° C with 5% CO2 for 6 h. 72 h after infection, success-
fully infected cells were selected with Puromycin (2.5 μg/
ml, Sigma) and analyzed for PIK3CA protein expression
by western blot.
Cell size and cell proliferation analysis
Cell size and cell proliferation were evaluated with
xCELLigence system (Roche), as previously described35.
In brief, 96-well microtiter plates that are specifically
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designed to measure cellular impedance (E-Plate, Roche)
were coated with 1% gelatin for 1 h at 37° C and then
saturated with 3% bovine serum albumin. In total, 2× 103
EC were resuspended in 0.1 ml of medium supplemented
with 10% FBS with or without VEGF-A (20 ng/ml, R&D
System) and transferred on E-Plates after background
measurement. The extent of cell proliferation and
spreading, measured as changes in impedance, was
monitored every 15 min for a total period of 48 h. The
measured impedance was expressed as relative impedance
(Cell Index). The Cell Index at each time point is defined
as (Rn-Rb)/(15Ω), where Rn is the cell-electrode impe-
dance of the well when it contains cells and Rb is the
background impedance of the well with the media alone.
Cell proliferation was also analyzed by Click-iT EdU
Alexa Fluor 647 Imaging kit. In brief, 10× 103 EC were
plated on gelatin-coated glass coverslips in 24-well plates
in 0.5 ml of medium supplemented with 10% FBS with or
without VEGF-A (20 ng/ml) for 24 h. When used, the
following inhibitors were added at the concentration of
100 nM: BEZ235, Everolimus and MK2206 (all from
Selleckchem). EdU was added to cells and left for another
24 h. Then cells were fixed and stained following manu-
facturer instructions. Four random fields of each sample
from three independent experiments were photographed
at the confocal microscope at low magnification and
Alexa Fluor 647 positive nuclei were counted. To measure
the proportion of EdU-positive cells and their size we
performed the same experiment on a glass bottom mul-
tiwell plate followed by a counterstaining with DAPI and
VE-Cadherin (R&D Systems). For each experiment (per-
formed in duplicate) a large (2.2 mm by 1.6 mm) image
was acquired using a Biotek Cytation reader (×10 objec-
tive). The VE-Cadherin staining channel was used to
extract cell outlines by means of Ilastik36 and overlapping
cells were manually separated in the images. Cell outlines
were then used to measure cell size. EdU and DAPI
staining channels were also segmented and cells with
overlapping DAPI and EdU staining were considered
positive. Segmentation and statistical analysis were per-
formed by means of custom written MATLAB algorithms.
The fraction of putative senescent cells was identified as
that of cells with area larger than 5000 µm2. This
threshold was chosen according to the area distribution of
the different mutants and by manually picking putative
senescent cells. To calculate the fraction of EdU-positive
cells in each category (<5000 µm2, normal and >5000
µm2, large) we just counted the number of positive large
cells among the total number of large cells, and corre-
spondingly the number of positive normal cells among the
total number of normal cells. The error was calculated
assuming that those numbers were distributed according
to a Poisson statistics. The final error was calculated with
standard error propagation methods.
Immunofluorescence microscopy
To analyze cell morphology, EC were plated on
gelatin-coated glass coverslips in 24-well plates.
After 3 h of adhesion, cells were fixed with 4% paraf-
ormaldehyde in PBS for 10 min. After fixation, cells were
rinsed three times with PBS, quenched with 50 mM
NH4Cl for 20 min at room temperature, washed twice
with PBS, and then permeabilized with PBS 0.2% Triton
X-100 for 8 min at room temperature. After two washes
with PBS, coverslips were blocked with PBS 1% donkey
serum for 1 h at room temperature, and incubated with
anti-paxillin (BD Biosciences) primary antibody over-
night at 4° C in a humidified chamber. After three washes
with PBS, coverslips were incubated for 1 h at 37° C in a
humidified chamber with fluorescent secondary anti-
bodies (donkey anti-rabbit Alexa Fluor 555, Thermo-
Fisher Scientific) and Phalloidin-Alexa Fluor 488
(ThermoFisher Scientific). Coverslips were then rinsed
three times with PBS, mounted, and analyzed using a
confocal laser-scanning microscope (TCS SP2 with DM
IRE2; Leica) equipped with ×63/1.40 HCX Plan-
Apochromat oil-immersion objective. Confocal images
are the maximum projections of a z section of ∼1.50 µm.
The images were arranged and labeled using Photoshop
software (Adobe).
Mice limbs were frozen in OCT compound and cut into
10 µm-thick sections after overnight treatment at 4° C in
30% sucrose solution. Tissue slices were fixed in 4%
paraformaldehyde for 10 min at room temperature. The
following antibodies were used: α-CD45 (Biolegend), α-
IB4 (Sigma), α-CD31 (BD Biosciences). The sections were
then incubated with the appropriate fluorescence-
conjugated secondary antibodies (Alexa Fluor 647 or
488, ThermoFisher Scientific), and nuclei were counter-
stained with DAPI (ThermoFisher Scientific). The sam-
ples were mounted using fluorescent mounting medium
(Dako). Images were captured and analyzed using a Leica
SPEII confocal laser-scanning microscope (Leica). Image
acquisition was performed maintaining the same laser
power, gain, and offset settings. Multiple independent
fields (15–20 for every sections; ×20 or ×40 magnifica-
tion) per tissue section were randomly chosen and ana-
lyzed from at least three limbs for each experimental
condition. Image quantification was performed using NIH
ImageJ and expressed as the fluorescence area. The
microvessel area was quantified by measuring the IB4+
area in the total field area.
Flow cytometry
To evaluate cell volume, EC were detached with trypsin,
washed with PBS and immediately analyzed on a Beckman
Coulter Cyan ADP. Forward scatter signal for each cell
type was obtained in basal condition and after treatment
with inhibitors previously described.
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Chemotaxis assay
Chemotaxis assays with human ECs were performed in a
Boyden chamber, as previously described36. In brief, PVP-
free polycarbonate filters (8 μm pore size; Neuroprobe) were
coated with 1% gelatin for 2 h at 37° C. A total of 10 ng/ml
VEGF-A dissolved in serum-free medium was seeded in the
lower compartment of the chamber; cells were serum
starved overnight, and then suspended in serum-free med-
ium at a concentration of 2.5× 106 cells/ml, and 50 μl of the
suspension was added to the upper compartment. After 5 h
of incubation at 37° C with 5% CO2, the upper surface of the
filters was scraped with a rubber policeman, and the filters
were fixed and stained with Diff-Quick (Dade Behring). Four
random fields of each sample in the lower surface of the
filters were counted at ×10 magnification.
Western blot analysis
For lysates, cells were serum deprived for 2 h and stimu-
lated or not with 30 ng/ml VEGF-A for 15min. When used,
inhibitors were added to cells for 1 h prior to growth factor
stimulation. Total proteins were extracted in Laemmli buffer
(2.5mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol), quantified
and equal amounts of each sample were resolved by SDS-
PAGE and transferred to PVDF membrane. After blocking
with TBS/0.1% Tween 20/5% BSA, membranes were incu-
bated with primary antibody overnight at 4° C. The following
primary antibodies were used: rabbit α-pY1175 VEGFR2, α-
VEGFR2, α-pS473 Akt, α-pT308 Akt, α-Akt, α-pS235/236 S6,
α-pS65 and pT37/46 4EBP1 (all from Cell Signaling Tech-
nology), α-β actin (Santa Cruz Biotecnology), α-p110 α
(ThermoFisher Scientific). Immunoreactive proteins were
identified with secondary antibody coupled to HRP antibody
and visualized by ECL. Quantification of the bands was done
by NIH ImageJ on representative western blots; band inten-
sities of phosphorylated Akt were normalized on total Akt,
and analogously those for phosphorylated VEGFR2 were
normalized on total VEGFR2, whereas band intensities of
phosphorylated S6 and 4EBP1 were normalized on β actin.
Spheroid sprouting assay
Spheroid sprouting assay was performed as previously
described37. In brief, EC spheroids were suspended in
medium with or without 20 ng/ml of VEGF-A, and
mixed with an equal volume of diluted collagen solution
(0.6 mg/ml). Capillary-like sprouts were examined with
inverted-phase contrast microscope (Leica) and photo-
graphed. To quantify spheroids growth (volume) and
sprouting we used the software Ilastik38. The software was
manually trained on a small dataset of images of spheroids
and segmented binary images were obtained. Equivalent
radii of the spheroids were measured with a custom
written Matlab algorithm, and normalized with control
average radius (unstimulated or VEGF-A vehicle-treated,
depending on the experiment). To quantify the sprouting,
an aspect ratio measure was used, defined as the ratio
between the equivalent ratios obtained by perimeter and
area of the spheroids.
Statistical analysis
When not differently indicated, data are presented as
average ± standard error (s.e.m.) of three independent
experiments. For in vitro assays, each experiment was
performed with a mix of EC from at least three different
umbilical cords. For in vivo experiments, cohorts of at
least two mice were subjected to each treatment (vehicle/
Tamoxifen or vehicle/4-OH Tamoxifen/4-OH Tamox-
ifen+ BEZ235 or Everolimus) and at least three inde-
pendent experiments were performed. Statistical
significance was determined by a Student’s t-test.
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